Literature DB >> 17254667

Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences.

E G Playford1, J C Craig, J R Iredell.   

Abstract

A retrospective case-control study was performed to assess risk factors and the clinical and economic consequences associated with acquisition of carbapenem-resistant Acinetobacter baumannii (CR-AB) in an intensive care unit (ICU) over a 24-month period. CR-AB was acquired by 64 of 1431 ICU admissions; each was matched with two controls. Risk factors associated with CR-AB acquisition included ICU-wide variables, such as 'colonization pressure' (the prevalence of ICU colonized patients) and ICU antibiotic use over the preceding three months, as well as patient-related variables. Among colonized patients, risk factors for CR-AB infection included transfusion and 'colonization density' (the proportion of body sites colonized with CR-AB). CR-AB infection was independently associated with increased hospital mortality [mortality difference: 20%; 95% confidence interval (CI): 1-40%], prolonged ICU stay (median length of stay difference: 15 days; 95% CI: 9-21 days) and prolonged hospital stay (30 days, 11-38 days) compared with matched controls.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17254667     DOI: 10.1016/j.jhin.2006.11.010

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  65 in total

Review 1.  Bloodstream infections in the Intensive Care Unit.

Authors:  Matteo Bassetti; Elda Righi; Alessia Carnelutti
Journal:  Virulence       Date:  2016-01-13       Impact factor: 5.882

Review 2.  Clinical and economic impact of common multidrug-resistant gram-negative bacilli.

Authors:  Christian G Giske; Dominique L Monnet; Otto Cars; Yehuda Carmeli
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

Review 3.  Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance.

Authors:  Vered Schechner; Elizabeth Temkin; Stephan Harbarth; Yehuda Carmeli; Mitchell J Schwaber
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

4.  Comparison of culture media for detection of Acinetobacter baumannii in surveillance cultures of critically-ill patients.

Authors:  A O Ajao; G Robinson; M S Lee; T D Ranke; R A Venezia; J P Furuno; A D Harris; J K Johnson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-12       Impact factor: 3.267

Review 5.  Association between infections caused by multidrug-resistant gram-negative bacteria and mortality in critically ill patients.

Authors:  Elisabeth Paramythiotou; Christina Routsi
Journal:  World J Crit Care Med       Date:  2016-05-04

6.  Nosocomial outbreak of carbapenem-resistant Acinetobacter baumannii in intensive care units and successful outbreak control program.

Authors:  Won Suk Choi; Su Hyun Kim; Eun Gyong Jeon; Myeung Hee Son; Young Kyung Yoon; Jung-Yeon Kim; Mi Jeong Kim; Jang Wook Sohn; Min Ja Kim; Dae Won Park
Journal:  J Korean Med Sci       Date:  2010-06-17       Impact factor: 2.153

7.  Multidrug resistant Acinetobacter baumannii: risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains.

Authors:  Jung-Jr Ye; Ching-Tai Huang; Shian-Sen Shie; Po-Yen Huang; Lin-Hui Su; Cheng-Hsun Chiu; Hsieh-Shong Leu; Ping-Cherng Chiang
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

8.  Multidrug resistant acinetobacter.

Authors:  Vikas Manchanda; Sinha Sanchaita; Np Singh
Journal:  J Glob Infect Dis       Date:  2010-09

Review 9.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

10.  In vitro activities of sitafloxacin tested alone and in combination with rifampin, colistin, sulbactam, and tigecycline against extensively drug-resistant Acinetobacter baumannii.

Authors:  Xiaomeng Dong; Fengzhe Chen; Yajun Zhang; Haihong Liu; Yongjuan Liu; Lixian Ma
Journal:  Int J Clin Exp Med       Date:  2015-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.